-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 22, CanSinoBio issued an announcement on the Hong Kong Stock Exchange stating that its recombinant new coronavirus vaccine for inhalation had been approved for clinical trials by the National Medical Products Administration.
The announcement issued by CanSino Bio at the Hong Kong Stock Exchange stated that the inhaled recombinant new coronavirus vaccine (type 5 adenovirus vector) developed in cooperation with the Institute of Bioengineering, Academy of Military Sciences, Academy of Military Sciences of the Chinese People’s Liberation Army has obtained national medicines.
The drug clinical trial approval issued by the Supervision and Administration Bureau became the first approved adenovirus vector new crown vaccine in China.
Earlier, CanSino Bio issued an announcement stating that based on the interim results of the phase 3 clinical trial, the company's recombinant new crown vaccine (type 5 adenovirus vector) Keweisha obtained emergency use authorization from the Hungarian National Institute of Medicine and Nutrition.
This is also the first time that Cansino has been approved by an EU member state.
The CanSino Bio-New Coronary Vaccine is a single-dose immunization.
According to its public Phase III clinical trial design, the recommended vaccination age for the vaccine is 18 years and older adults, and there is no upper age limit.
In terms of vaccine effectiveness, according to The Paper, the current global Phase III clinical data of the vaccine shows that 28 days after a single injection of the vaccine, the overall protective efficacy of Cansino Bio-New Crown vaccine is 65.
28%.
In addition, some subjects in the domestic phase I clinical trial conducted a 6-month booster immunization study, and the results showed that the antibody level increased by 10 times or more after the 6-month booster immunization.
It is worth noting that the Cansino Bio-New Coronary Vaccine and the recent AstraZeneca/Oxford New Coronary Vaccine, which has been deeply involved in thrombosis and other adverse reactions, belong to the technical route of adenovirus vectors.
Previously, more than 10 EU countries suspended AstraZeneca/Oxford Covid-19 vaccine.
Following the European Medicines Agency’s announcement on March 18 that the AstraZeneca/Oxford Covid-19 vaccine was “safe and effective”, France, Germany and other countries The vaccination was resumed one after another.In the report of The Paper, CanSinoBio emphasized that according to the interim data of the global multi-center Phase III clinical trial, no serious adverse reactions related to the vaccine have occurred.
Based on the data of its protective efficacy, the vaccine has good safety.
And effectiveness, especially in the elderly population, the incidence of adverse reactions is lower.
Article source: 1.
Observer Network "Cansino New Crown Vaccine Approved by EU Member States for the First Time"
The announcement issued by CanSino Bio at the Hong Kong Stock Exchange stated that the inhaled recombinant new coronavirus vaccine (type 5 adenovirus vector) developed in cooperation with the Institute of Bioengineering, Academy of Military Sciences, Academy of Military Sciences of the Chinese People’s Liberation Army has obtained national medicines.
The drug clinical trial approval issued by the Supervision and Administration Bureau became the first approved adenovirus vector new crown vaccine in China.
Earlier, CanSino Bio issued an announcement stating that based on the interim results of the phase 3 clinical trial, the company's recombinant new crown vaccine (type 5 adenovirus vector) Keweisha obtained emergency use authorization from the Hungarian National Institute of Medicine and Nutrition.
This is also the first time that Cansino has been approved by an EU member state.
The CanSino Bio-New Coronary Vaccine is a single-dose immunization.
According to its public Phase III clinical trial design, the recommended vaccination age for the vaccine is 18 years and older adults, and there is no upper age limit.
In terms of vaccine effectiveness, according to The Paper, the current global Phase III clinical data of the vaccine shows that 28 days after a single injection of the vaccine, the overall protective efficacy of Cansino Bio-New Crown vaccine is 65.
28%.
In addition, some subjects in the domestic phase I clinical trial conducted a 6-month booster immunization study, and the results showed that the antibody level increased by 10 times or more after the 6-month booster immunization.
It is worth noting that the Cansino Bio-New Coronary Vaccine and the recent AstraZeneca/Oxford New Coronary Vaccine, which has been deeply involved in thrombosis and other adverse reactions, belong to the technical route of adenovirus vectors.
Previously, more than 10 EU countries suspended AstraZeneca/Oxford Covid-19 vaccine.
Following the European Medicines Agency’s announcement on March 18 that the AstraZeneca/Oxford Covid-19 vaccine was “safe and effective”, France, Germany and other countries The vaccination was resumed one after another.In the report of The Paper, CanSinoBio emphasized that according to the interim data of the global multi-center Phase III clinical trial, no serious adverse reactions related to the vaccine have occurred.
Based on the data of its protective efficacy, the vaccine has good safety.
And effectiveness, especially in the elderly population, the incidence of adverse reactions is lower.
Article source: 1.
Observer Network "Cansino New Crown Vaccine Approved by EU Member States for the First Time"